Chengdu Endos Biotechnology

Chengdu Endos Biotechnology is a clinical-stage biotechnology company focused on developing innovative enzymatic therapies for antibody-mediated autoimmune diseases and organ transplant rejection. The company utilizes its proprietary protein engineering platform to optimize Endoglycosidase S (Endo-S), an enzyme capable of specifically degrading Immunoglobulin G (IgG) to neutralize pathogenic autoantibodies. Its lead candidate, EDS-101, is currently in clinical development for indications including immune thrombocytopenic purpura (ITP) and myasthenia gravis. By leveraging its expertise in enzyme engineering, Chengdu Endos aims to provide rapid-acting treatments for acute immunological flares and facilitate desensitization in transplant patients. The company is headquartered in the Chengdu Hi-tech Zone and maintains strong collaborative ties with leading academic institutions in China.